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Abstract: Solid lipid nanoparticles (SLNs) formulated from one type of lipid (homolipid) 
suffer from low drug encapsulation and drug bursting due to crystallization of the lipid into the 
more ordered β modification, which leads to decreased drug entrapment and faster drug release. 
This study assessed the feasibility of using nanostructured lipid matrices (NLMs) for ocular 
delivery of methazolamide-(MZA) adopting heterolipids composed of novel mixtures of 
  Compritol® and cetostearyl alcohol (CSA), and stabilized by Tween 80®. The systems were 
prepared using the modified high shear homogenization followed by ultrasonication method, 
which avoids the use of organic solvents. A 32 full factorial design was constructed to study the 
influence of two independent variables, namely the ratio of CSA:Compritol and the concentra-
tion of Tween 80, each in three levels. The dependent variables were the entrapment efficiency 
percentages (EE%), mean particle size (PS), polydispersity index (PDI), and zeta potential (ZP). 
In vivo intraocular pressure (IOP) lowering activity for the selected formulae was compared to 
that of MZA solution. The results showed that increasing the ratio of CSA to Compritol increased 
the EE% and PS, while increasing the concentration of Tween 80, decreased PS with no signifi-
cant effect on EE%. The ZP values of all formulae were positive, and greater than 30 mV . The 
best formula, composed of 4% CSA, 2% Compritol, 0.15% stearylamine, and 2% Tween 80, 
with EE% of 25.62%, PS of 207.1 nm, PDI of 0.243, and ZP of 41.50 mV , showed in vitro 
sustained release properties for 8 hours and lowered the intraocular pressure by 8.3 mmHg 
within 3 hours, with this drop in pressure lasting for 12 hours.
Keywords: nanostructured lipid matrices, heterolipids, factorial design, cetostearyl alcohol, 
methazolamide, ocular delivery
Introduction
Conventional ocular drug delivery systems such as eye drops suffer from very poor 
bioavailability because the eye is protected by complicated defense mechanisms that 
make it difficult to achieve an effective drug concentration in the target area. Colloidal 
drug delivery systems such as liposomes and emulsions have been developed to solve 
this problem,1,2 but they suffer from poor stability. Solid lipid nanoparticles (SLNs) 
are colloidal particles developed as an alternative to emulsions, liposomes, and poly-
meric nanoparticles for the delivery of hydrophilic, lipophilic, and/or poorly water 
soluble drugs. They have a number of advantages including the use of biodegradable, 
biocompatible, and physiological lipids, the avoidance of organic solvents during 
preparation, high bioavailability, and the possibility of large-scale production and 
sterilization.3–5 The solid matrix of SLNs tightly binds the drug molecules and so 
releases incorporated drugs more slowly than conventional fluid colloidal lipid drug 
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carriers, while also improving the stability of drugs against 
decomposition. SLNs enhance ocular drug delivery by facili-
tating corneal penetration due to their lipophilic character,6 
and ensure adherence to ocular membranes, while their small 
size and particulate nature prevents tear wash out.7
However, SLNs formulated from a single type of lipid 
(homolipid) suffer from low drug encapsulation and possible 
drug bursting due to crystallization of the lipid into the more 
ordered β modification,5 which shows a high degree of order 
and limited imperfections in the crystal lattice.8 The use of 
mixtures of lipids which do not form a highly ordered crys-
talline arrangement is needed to overcome these limitations. 
Such a lipid matrix could be achieved by using a combination 
of solid lipid and oil, which is termed a nanostructured lipid 
carrier,9 or through the use of a solid lipid mixture (hetero-
lipids) with a complex nature that includes different chain 
lengths and melting points, which is called a nanostructured 
lipid matrix (NLM).10,11 Mixing lipids modifies the polymor-
phic properties of the single lipid, and has been proven to 
produce lipid matrices of low crystallinity.10
Compritol and cetostearyl alcohol (CSA) has not previ-
ously been studied for the preparation of NLMs. Compritol 
is generally regarded as safe (GRAS), and is a biocompat-
ible, nonirritant, and   nontoxic partial triglyceride of behenic 
acid (C21H43COOH). It is mainly composed of glyceryl 
dibehenate with variable quantities of glyceryl mono- and 
tribehenate. CSA is a mixture of solid aliphatic fatty alcohols 
consisting primarily of stearyl alcohol (1-octadecanol, 
C18H37OH) and cetyl alcohol (1-hexadecanol, C16H33OH). 
It is commonly used in cosmetics and topical preparations, 
and is generally regarded as nontoxic and nonirritant to 
the eyes.12
Methazolamide (MZA) is a sulfonamide derivative that 
is weakly acidic, and slightly soluble in water. It is a sys-
temically administered carbonic anhydrase inhibitor (CAI) 
used for the treatment of glaucoma, but it possesses some 
side effects such as numbness and tingling of extremities, 
a metallic taste, and metabolic acidosis due to the presence 
of carbonic anhydrase enzyme in many tissues and organs. 
Topical administration of MZA directly to the eye may 
reduce systemic side effects, but MZA’s poor aqueous solu-
bility (1.7 mg/mL at 25°C)13 and low corneal permeability 
(1.75 × 10−4 cm/hour)14 make topical administration difficult. 
Previous attempts have been made to formulate topical MZA 
including MZA cyclodextrin eye drops,15 MZA calcium 
phosphate nanoparticles,16 MZA in situ gels,17 and MZA 
solid lipid nanoparticles by modified emulsion-solvent 
evaporation (which involved the use of organic solvents).18 
MZA   cyclodextrin eye drops increased aqueous solubility 
of MZA, however there still exists the possibility of tissue 
irritation and toxicological implications caused by the use 
of cyclodextrin as a penetration enhancer.19 Also, using 
SLNs composed of homolipid were not successful in sustain-
ing drug release, with approximately 77% released in the 
first hour.18
The objective of this study was to assess the feasibility 
of using NLMs for ocular delivery of MZA-adopting het-
erolipids composed of novel mixtures of Compritol and CSA 
stabilized by Tween®. The NLMs were prepared using the 
modified high shear homogenization followed by ultrasoni-
cation method, which avoids the use of organic solvents.20 
The use of heterolipids was expected to create imperfections 
in the crystal lattice, providing more space that can localize 
more drug, and thus improving the entrapment efficiency. 
A 32 full factorial design was built up to optimize the pro-
duction process by studying the effect of using different 
CSA:Compritol ratios and various concentrations of Tween 
80 on entrapment efficiency percentages (EE%), mean 
particle size (PS), polydispersity index (PDI), and zeta 
potential (ZP). The intraocular pressure (IOP) lowering 
activity was evaluated in rabbits’ eyes and compared to that 
of MZA solution.
Materials and methods
Materials
Methazolamide (MZA) was purchased from Jiaxing 
Taixing Chemical and Pharm Co, Ltd, (Jiaxing, China). 
Compritol® 888 ATO was kindly gifted by Gattefossé 
(Saint-Priest, France). Stearylamine (SA) was purchased 
from Sigma Chemical Co, Tween 80, cetostearyl alcohol 
(CSA), potassium dihydrogen phosphate, disodium hydro-
gen phosphate, and sodium chloride were purchased 
from Adwic, El-Nasr Pharmaceutical Co, (Cairo, Egypt). 
Spectra/Por dialysis membrane (12,000–14,000 molecular 
weight cut off) was purchased from Spectrum Laboratories 
Inc, (Rancho Dominguez, CA). Benoxinate hydrochloride 
eye drops 0.4% (w/v) was purchased from Egyptian 
International Pharmaceutical Industries (EIPICO) (Cairo, 
Egypt).
Design of the experiments
A 32 full factorial design was built up for optimization of 
the preparation of cationic MZA-loaded NLMs. The study 
design involved the investigation of the effect of two inde-
pendent variables, namely lipid composition (X1) and per-
centage of Tween 80 (X2). Lipid composition was studied 
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Table 1 The factorial design independent variables and their levels
Variables Levels
X1: CSA:Compritol® (wt%) 2:4 3:3 4:2
X2: Tween 80® (wt%) 0.5 1 2
Abbreviation: CSA, cetostearyl alcohol.
by changing the ratio of CSA to Compritol so that this was 
2:4, 3:3, and 4:2 wt%; the percentage of Tween 80 was 
studied at 0.5, 1, and 2 wt%. The dependent variables inves-
tigated were the entrapment efficiency percentages (Y1), 
mean particle size (Y2), polydispersity index (Y3), and zeta 
potential (Y4) of MZA-loaded NLMs. For comparative 
purposes, conventional SLNs were also prepared using 
Compritol. A typical design of the full factorial experiment 
is displayed in Table 1, and the composition of different 
formulae is shown in Table 2.
Preparation of MZA-loaded NLMs
Cationic MZA-loaded NLMs and SLNs were prepared by 
the modified high shear homogenization followed by ultra-
sonication method.20 The total amount of the lipid phase in 
the developed formulations was kept constant at 6 wt%. The 
lipid phase was composed of Compritol or Compritol 
together with CSA and 0.15 wt% stearylamine, and was 
heated to 80°C before 20 mg MZA was dispersed in the 
molten lipids. An aqueous surfactant solution containing 
various concentrations of Tween 80 was heated to approxi-
mately the same temperature, and then poured into the hot 
lipid phase. Homogenization was carried out at 15,200 rpm 
for 5 minutes using a homogenizer (Ultra Turrax T25; IKA, 
Staufen, Germany). Both the lipid and the aqueous phases 
were heated to 80°C and stirred on magnetic stirrers (Yellow 
Line MAG HS 7, IKA). The obtained coarse hot oil in water 
emulsion was ultrasonicated for 30 minutes in a warmed bath 
sonicator at 40°C (Crest Ultrasonics, ETL testing   laboratories, 
Cortland, NY), and SLNs and NLMs were obtained by 
  allowing the hot nanoemulsion to cool to room temperature 
before being refrigerated at 4°C. All of the above steps were 
done under aseptic conditions. All glassware were sterilized 
by autoclaving, and the entire procedure was carried out in 
a laminar flow hood (Esco, Singapore). All batches were 
prepared in triplicate.
Determination of MZA entrapment 
efficiency
The EE% of MZA in SLNs and NLMs was determined by 
measuring the concentration of free drug in the 
nanoemulsion. The non-encapsulated MZA was separated by 
filtration/  centrifugation using Nanosep® centrifuge tubes fitted 
with an ultra-filter (MWCO100KD; Pall Life Sciences, Port 
  Washington, NY). A definite volume of the prepared NLM 
dispersion was diluted with distilled water, from which 500 µL 
was transferred to the upper chamber of the Nanosep. The 
Nanosep was centrifuged at 9000 rpm at 20°C for 2 hours 
(Z216 MK; Hermle, Gosheim, Germany). The amount of free 
drug in the filtrate was determined spectrophotometrically at 
290 nm using a UV-visible spectrophotometer (model UV-1601 
PC; Shimadzu, Kyoto, Japan). The UV-  spectrophotometric 
analysis method was developed and validated in our laboratory. 
The EE% was calculated as follows:
  EE%
WW
W
tf
t
=
−
×

 

  100   (1)
where Wt is the total amount of drug used in the formulation 
and Wf is the amount of free drug remaining in the 
supernatant.
Particle size and zeta potential analysis
The PS, PDI, and ZP of SLNs and NLMs were determined 
through dynamic light scattering (DLS, Zetasizer Nano ZS, 
Malvern instruments, Malvern, UK) at 25°C using disposable 
polystyrene cells and disposable plain folded capillary zeta 
cells. The samples were diluted with distilled filtered water 
before measurement. For PS analysis, a measurement angle 
of 173° was used with the backscattering technique, while 
the ZP was calculated from the electrophoretic mobility using 
the Helmholtz–Smoluchowski equation. Measurements were 
performed in triplicate.
Electron microscope examination
The morphological observation of MZA-loaded NLMs was 
performed by transmission electron microscope (TEM) 
(JEM-1010; JEOL Ltd, Tokyo, Japan). One drop of the NLM 
suspension was deposited on a carbon-coated copper grid 
and then examined at 40 or 60 kV .
In vitro release of MZA from NLMs
In vitro drug release studies were performed using the 
dialysis membrane diffusion technique. The dialysis 
membrane of MWCO 12,000–14,000 (Spectra/Por) was 
used as this retained NLMs but allowed free drug into the 
release media. An accurately measured amount equivalent 
to 1 mg MZA was transferred to a 2.5 cm diameter glass 
tube 10 cm in length that was open at both ends, with its 
lower end covered with the membrane presoaked in distilled 
water.21,22 The cylinder was fitted to the shaft and immersed 
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Table 2 Composition of the prepared MZA-loaded NLM and SLN formulations, and their measured responses
Formulation  
code
Formulation compositiona Measured responses
CSA:Compritol  
(wt%)
Tween 80  
(wt%)
EE (%) ± SE Mean size  
(nm) ± SE
PDI ZP  
(mV) ± SE
NLM-1 2:4 0.5 14.57 ± 1.12 336.80 ± 4.00 0.218 53.25 ± 1.02
NLM-2 3:3 0.5 15.32 ± 0.84 416.50 ± 4.82 0.234 52.95 ± 0.45
NLM-3 4:2 0.5 27.97 ± 0.16 482.60 ± 0.24 0.267 52.65 ± 0.20
NLM-4 2:4 1 13.91 ± 2.27 317.85 ± 1.18 0.247 51.25 ± 0.28
NLM-5 3:3 1 22.24 ± 0.72 347.70 ± 1.80 0.275 49.85 ± 0.04
NLM-6 4:2 1 27.35 ± 1.45 391.70 ± 4.65 0.337 50.85 ± 0.69
NLM-7 2:4 2 16.91 ± 0.63 206.30 ± 8.08 0.230 42.45 ± 0.12
NLM-8 3:3 2 21.03 ± 0.76 196.20 ± 7.19 0.248 43.15 ± 0.28
NLM-9 4:2 2 25.62 ± 0.89 207.10 ± 6.45 0.243 41.50 ± 0.33
SLN-1 0:6 2 11.29 ± 0.58 157.25 ± 1.13 0.240 38.30 ± 0.00
Note: aAll formulations contain 0.15 wt% stearylamine and 20 mg MZA.
Abbreviations: CSA, cetostearyl alcohol; EE, entrapment efficiency; MZA, methazolamide; NLM, nanostructured lipid matrices; PDI, polydispersity index; SE, standard error 
of mean; SLN, solid lipid nanoparticles; ZP, zeta potential. 
in the   dissolution flask of the dissolution apparatus USP 
(Pharma Test, Hamburg, Germany) containing 50 mL 
phosphate-buffered saline (PBS) solution (pH 7.4).6 This 
volume provided complete sink conditions for the MZA. 
The entire system was kept at 37°C ± 0.5°C with continuous 
stirring at 50 rpm. At different time intervals (0.25, 0.5, 
0.75, 1, 1.5, 2, 4, 6, and 8 hours), samples were withdrawn, 
replaced by fresh buffer, and assayed spectrophotometrically 
at 289 nm. All the results presented are the mean values 
of three runs.
Differential scanning calorimetry
The thermal properties of pure MZA, a physical mixture 
composed of Compritol, CSA, MZA and stearylamine in 
same ratio of NLM-9 unloaded NLMs, and MZA-loaded 
NLMs formula NLM-9 were investigated using differential 
scanning calorimetry (DSC 60; Shimadzu). Samples 
(3–5 mg) were sealed in aluminum pans with lids and heated 
at a rate of 10°C/minute to a temperature of 300°C, using 
dry nitrogen as a carrier gas with a flow rate of 25 mL/minute. 
Indium was used as the standard   reference material to cali-
brate the energy and scales temperature of the instrument.
X-ray diffraction
X-ray diffraction experiments were performed on pure MZA, 
Compritol, CSA, and the selected MZA NLM formula 
NLM-9 using an X-ray diffractometer (X-pert; Philips, 
Guildford, UK). The patterns of the samples were recorded 
with an area detector operating at 40 kV and 30 mA using 
CuKa radiation (k =  0.154  nm)  and  X-ray  tube 
(PW3373/00CuLFF). X-ray diffractograms were obtained 
at a scanning rate of 1.2°/minute and the scanning scope of 
2θ was from 50 to 400 at room temperature.
Effect of aging on PS
The selected MZA NLM formulations were sealed in glass 
vials and stored in a refrigerator at 4°C. Samples from each 
batch were withdrawn after storage for 1 month to study 
the effect of storage on PS of NLMs. The DLS technique 
(Zetasizer Nano ZS, Malvern Instruments) was used, as 
discussed above.
In vivo study of cationic MZA-loaded 
NLMs
Cationic MZA-loaded NLM formulations that showed high 
EE% and suitable PS were selected to be tested for their 
intraocular pressure lowering effect on adult albino normo-
tensive rabbits, and the results were compared to that of MZA 
solution. All preparations used in this study were adjusted to 
a concentration of 0.15% w/v MZA. Albino rabbits of average 
weight 2.5–3 kg were randomly divided into three groups, 
each consisting of three rabbits: Group I received MZA solu-
tion, Group II received formula NLM-6, and Group III 
received formula NLM-9. The rabbits were kept in individual 
cages with food and water, and were maintained in a 12-hour 
light/12-hour dark cycle in a temperature controlled room at 
20°C–24°C.23 A single 50 µL dose of each preparation was 
administered at room temperature and instilled in the lower 
conjunctival sac corneal surface of the rabbit’s left eye. The 
IOP was measured as a function of time using a standardized 
tonometer (Shiotz, Riester, Germany),24 by the same operator 
after instilling one drop of 0.4% (w/v) benoxinate hydrochlo-
ride to the eye as a local anesthetic. IOP was first measured 
immediately before drug administration, then at 1, 2, 3, 4, 5, 
6, 7, 8, 10, and 12 hours. In all the experimental rabbits, the 
right eye was left as a control. The ocular hypotensive activity 
was expressed as the average difference in IOP between the 
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treated eye and the control eye to decrease the diurnal, seasonal, 
and individual variations usually observed in rabbits.23 The 
experimental procedures were performed according to ethical 
principles on the use of animals.24 The protocol of the study 
was approved by the ethical committee of the Egyptian 
Research Institute of Ophthalmology, Giza (Egypt).
Data analysis
Data were compared using a one-way analysis of variance 
(ANOVA) followed by Tukey–Kramer multiple comparisons 
test or Student’s t-test using a demonstration version of Graph-
Pad InStat 3 software (GraphPad Software, La Jolla, CA). The 
factorial experiment design and analysis was performed using 
Minitab® (v 15.1; Minitab Inc, State College, PA).
Results and discussion
The UV spectrophotometric analysis method used for the 
in vitro assay of MZA was developed and validated in our 
laboratory and was found to be linear over the range of 
5–20 µg/mL, while the limit of detection and limit of quan-
tification were found to be 0.125 µg/mL and 0.379 µg/mL, 
respectively. The regression equation was y = 0.0459x − 
0.00398 where y is the absorbance and x is the concentration 
of MZA in µg/mL (r = 0.9993).
MZA-loaded NLMs were successfully prepared through 
the use of the modified high shear homogenization followed 
by ultrasonication method, which has the advantage of avoid-
ing toxic organic solvents. Heterolipid mixtures of Compritol 
and CSA were used to increase the EE% of MZA in the 
prepared formulations.
Preliminary studies (data not shown) were carried out to 
determine the factors to be included in the factorial design. 
CSA was compared to the results obtained from cetyl alcohol 
and Gelucire® 44/14 (Gattefossé, Saint-Priest, France) and 
was found to be the most appropriate fatty alcohol to be 
mixed with Compritol. Different amounts of MZA were 
tested for entrapment into the prepared formulations, with 
20 mg found to be the most effective; this amount was used 
in all the prepared formulations.
Tween 80 was the surfactant of choice because of its 
non-ionic character and excellent ocular tolerability as it is 
reported to be non-irritating to the rabbits’ eyes up to a 
concentration of 10%.25 Stearylamine (SA) has been com-
monly used in preparing cationic emulsions intended for 
ocular drug delivery and was found to be non-irritating, 
with no evidence of inflammatory or toxic response when 
instilled in rabbits’ eyes.26 SA was chosen to serve multiple 
roles. The first of these was to impart a positive charge to 
produce cationic NLMs that could elicit electrostatic adhe-
sion or interaction with the negatively charged mucin of 
the corneal epithelium, hence increasing ocular contact time 
and providing prolonged release.22 The second role was to 
enhance EE%, as MZA is a weak acid and will undergo 
electrostatic interaction with the positively charged SA. 
This increase in EE% was confirmed in our preliminary 
studies. Finally, SA also acts as a co-surfactant for further 
PS reduction.
Effect of variables on optimized  
MZA NLMs
EE% response
Table 2 shows that the EE% of the prepared NLM formulations 
were in the range of 13.91% to 27.97%, which were higher 
than that of the SLN formula (SLN-1) containing Compritol 
only which gave the lowest EE% of value 11.29%. This con-
firms that using heterolipids gave a better EE% than a 
  homolipid. This may be due to the fact that mixtures of lipids 
created defects in the crystal lattice, providing more room for 
the entrapment of MZA into the prepared NLM formulations.27 
Table 3 shows that only CSA:Compritol ratio had a significant 
effect on MZA entrapment into NLMs (P , 0.001) while 
Tween 80 concentration had no significant effect.
Table 3 ANOVA analysis for dependent variables (EE% and PS)
Source of  
variation
DF EE (%) PS (nm)
Sum of  
squares
Mean  
square
F value Sum of  
squares
Mean  
square
F value
CSA:Compritol 2 646.302 323.151 158.89s 24376 12188 307.05s
Tween 80 2 21.473 10.736 5.28 208222 104111 2622.86s
CSA:Compritol 
Tween 80
4 84.211 21.053 10.35s 16108 4027 101.45s
Error 17 34.574 2.034 – 675 40 –
Total 26 786.561 – – 249380 – –
Note: SSignificant at P , 0.001.
Abbreviations: ANOVA, analysis of variance; CSA, cetostearyl alcohol; DF, degrees of freedom; EE, entrapment efficiency; PS, particle size.
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Figure 1A shows that increasing CSA concentration from 
2 to 4 wt% significantly increased the mean EE% values of 
MZA in the prepared formulations from 15.13% to 26.98% 
(P , 0.001). This could be explained by CSA being a mixture 
of solid aliphatic alcohols consisting mainly of stearyl alcohol 
and cetyl alcohol – both have an alcohol group while Compritol 
is mainly composed of glyceryl dibehenate, which is an ester 
of behenic acid. The presence of the alcohol group and its 
lower number of carbon atoms means that CSA is relatively 
less hydrophobic than Compritol. MZA is a relatively hydro-
philic drug with log p = −0.2, so CSA provided a good medium 
for its entrapment, and this entrapment increases with increas-
ing CSA ratio. This agrees with previous results where fatty 
alcohols were found to be capable of creating a less ordered 
solid lipid matrix, leaving space for the accommodation of 
drug molecules.28 Moreover, fatty alcohols such as cetyl alco-
hol were reported to successfully entrap hydrophilic drugs 
such as buspirone HCl29 and Pentoxyfilline.30
Figure 1B and Table 3 show that there was a significant 
two way interaction between the lipid composition and 
Tween 80 concentration. The prepared formulations with 4:2 
(CSA:Compritol) wt% ratio (NLM-3, NLM-6, and NLM-9) 
gave the highest EE% at all levels of Tween 80, followed by 
3:3 (NLM-2, NLM-5, and NLM-8) and 2:4 (NLM-1, NLM-4, 
and NLM-7) wt% ratios, respectively, as previously 
d  iscussed. It was also found that increasing the ratio of 
CSA:Compritol from 2:4 to 3:3 wt% the ratio at 0.5 wt% 
Tween 80 (Formula NLM-2) did not result in a significant 
increase in the EE% when compared to formula NLM-1.
Particle size and polydispersity  
index response
The results of PS and PDI of the freshly prepared MZA 
formulations are presented in Table 2. All NLM   formulations 
showed a mean PS below 500 nm, and ranged from 
196.2 nm to 482.6 nm. This is an excellent size for ocular 
delivery as the human eye can tolerate particles as large as 
10 µm.31 PDI values ranged from 0.218 to 0.337. Tables 3 
and 4 show that both the CSA:Compritol ratio and Tween 
80 concentration had significant effects on MZA-loaded 
NLM particle size and PDI (P , 0.001). Furthermore, 
a significant two-way interaction (P , 0.001) was observed 
between lipid composition and Tween 80 concentration on 
PS and PDI, which indicates that both PS and PDI are 
dependent on these factors.
Figure 2A shows that increasing CSA concentration from 
2 to 4 wt% significantly increased the PS from 286.9 nm to 
360.4 nm (P , 0.001), while increasing Tween 80 concen-
tration from 0.5 to 2 wt% caused PS to drop from 412 nm 
to 203.2 nm (P , 0.001). Figure 3A shows that increasing 
CSA concentration from 2 to 4 wt% increased the PDI from 
0.231 to 0.282 (P , 0.001), while increasing Tween 80 
concentration from 0.5 to 1 wt% resulted in an increase in 
PDI from 0.240 to 0.286, but PDI dropped to 0.240 when 
Tween 80 concentration reached 2 wt%. Similar results for 
the effect of Tween 80 on PDI were obtained in a previous 
study of the incorporation of flurbiprofen into lipid 
nanoparticles.32
The positive effect of increasing CSA ratio on PS enlarge-
ment may be due to the deposition of CSA on the surface of 
the solidified Compritol, as Compritol has a higher melting 
point (65°C–77°C) and will start solidifying earlier than CSA 
(which has a melting point of 48°C–56°C). Also, as the ratio 
of CSA increases the EE% of MZA increases, as previously 
discussed, which also results in an increase in PS due to an 
increase in the amount of the drug entrapped in the NLMs. 
On the other hand, the effect of Tween 80 on PS reduction 
could be attributed to the larger amount of surfactant 
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Figure 1 Main effect (A) and interaction plot (B) for EE% of MZA in NLMs.
Abbreviations: CSA, cetostearyl alcohol; EE, entrapment efficiency; MZA, methazolamide; NLMs, nanostructured lipid matrices.
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Figure 2 Main effect (A) and interaction plot (B) for PS of MZA-loaded NLMs.
Abbreviations: CSA, cetostearyl alcohol; MZA, methazolamide; PS, particle size.
  available to cover the lipid surface, which lowers the inter-
facial tension and allows smaller particles to be formed.33,34
Data presented in Tables 3 and 4 indicate that there was a 
significant two-way interaction (P , 0.001) between lipid 
composition and Tween 80 concentration concerning PS and 
PDI. As the Tween 80 percentage increased from 0.5 to 2 wt%, 
the effect of PS enlargement caused by increasing CSA ratio 
diminished until it disappeared at 2 wt% Tween 80. This gave 
a similar mean PS regardless of the ratio of CSA (Figure 2B).
Zeta potential response
The results of Zeta potential (ZP) are displayed in Table 2. 
All MZA-NLM systems carried a positive charge due to the 
presence of stearylamine. The ZP values were higher than 
30 mV , ranging from 41.5 mV to 53.25 mV which indicates 
that particle aggregation is less likely to occur due to elec-
trostatic repulsion between particles with same electrical 
charge producing stable dispersions.
Table 4 shows that only Tween 80 concentration had a 
s  ignificant effect on MZA-loaded NLMs ZP (P , 0.001) 
while CSA:Compritol ratio had no significant effect. 
  Figure 4A shows that increasing Tween 80 concentration 
from 0.5 to 2 wt% decreased the ZP from 52.90 mV to 
42.26 mV (P , 0.001). This is due to the nonionic character 
of Tween 80 reducing the positive charge expressed on the 
surface of nanoparticles.35 From the results   illustrated in 
Figure 4B and tabulated in Table 4, it is clear that there was 
no significant two-way interaction (P , 0.001) between lipid 
composition and Tween 80 concentration.
Electron microscope examination
Morphological examination of representative MZA-loaded 
NLM formulations (NLM-5, NLM-6, and NLM-9) was 
performed using TEM (see Figure 5). This revealed that all 
the prepared particles were spherical in shape without aggre-
gation, with an increase in mean PS correlated with increasing 
CSA ratio (Figure 5A and   B), and a decrease in mean PS 
correlated with increasing Tween 80 concentration 
(  Figure 5C) as was previously discussed.
In vitro release of MZA from NLMs
Release studies were carried out on MZA-loaded NLM 
formulae NLM-5, NLM-6, and NLM-9, which gave the 
highest EE% and suitable particle sizes ranging from 
Table 4 ANOVA statistical analysis for dependent variables (PDI and ZP)
Source of  
variation
DF PDI ZP (mV)
Sum of  
squares
Mean  
square
F value Sum of  
squares
Mean  
square
F value
CSA:Compritol 2 0.0117 0.0059 53.27s 2.105 1.053 3.18
Tween 80 2 0.0128 0.0064 58.22s 563.945 281.973 850.67s
CSA:Compritol − 
Tween 80
4 0.0053 0.0013 12.03s 6.950 1.738 5.24
Error 17 0.0018 0.0001 – 5.635 0.331 –
Total 26 0.0317 – – 578.650 – –
Note: SSignificant at P , 0.001.
Abbreviations: ANOVA, analysis of variance; CSA, cetostearyl alcohol; DF, degrees of freedom; PDI, polydispersity index; ZP, zeta potential.
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Figure 4 Main effect (A) and interaction plot (B) for ZP of MZA-loaded NLMs.
Abbreviations: CSA, cetostearyl alcohol; MZA, methazolamide; NLMs, nanostructured lipid matrices, ZP, zeta potential.
207.1 nm to 391.7 nm. The results were compared with 
MZA-entrapped SLN formula SLN-1. The release profiles 
shown in Figure 6 revealed that entrapment of MZA into 
NLMs sustained and controlled the release of the drug over 
a prolonged period. The sustained effect was dependent on 
the lipid mixture ratio (3:3 or 4:2 CSA:Compritol wt%) and 
percentage of Tween 80 (1 or 2 wt%). The release patterns 
can be arranged in the following prolonged order: 
NLM-6 . NLM-9 . NLM-5 . SLN-1.
The common feature in these profiles was an initial burst 
effect with approximately 30.68%, 36.12%, 39.27%, and 
43.31% of drug being released in the first hour for NLM-6, 
NLM-9, NLM-5, and SLN-1, respectively. This was followed 
by a slower exponential release of the remaining drug with 
approximately 75.37%, 84.88%, 90.03%, and 97.85% of 
drug being released over the following 8 hours, respectively. 
It is clear that using a mixture of lipids could decrease the 
burst effect and sustain MZA release better than a single lipid 
alone, as this provided the fastest release. The initial burst 
effect could be attributed to the portion of the drug that was 
positioned on the outer shell of the NLMs, this is followed 
by the slower release of the remaining drug that was entrapped 
inside the core of the NLMs. The presence of the drug in the 
outer shell of the NLMs has been explained as a result of 
reduction in drug solubility in the aqueous phase during 
solidification of NLMs. This forces the drug to go to the lipid 
phase that has already been recrystallized and so is prevented 
from entering the lipid core, which means that it is concen-
trated on the surface of the NLMs.3,36
By further inspection of the release profiles it was concluded 
that increasing the CSA content from 3 wt% (NLM-5) to 
4 wt% (NLM-6, NLM-9) reduced MZA release. Formula 
NLM-6 showed the slowest release pattern, reaching about 
75% of MZA released over 8 hours. This may be attributed 
Main effects plot for PDI Interaction plot for PDI
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Figure 3 Main effect (A) and interaction plot (B) for PDI of MZA-loaded NLMs.
Abbreviations: CSA, cetostearyl alcohol; MZA, methazolamide; PDI, polydispersity index.
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to the higher EE% of MZA and larger PS in formula 
NLM-6, which meant that a smaller surface area was 
exposed to the release medium. From the results of 
formulations containing 4 wt% CSA, we can conclude that 
increasing the Tween 80 concentration from 1 wt% (NLM-6) 
to 2 wt% (NLM-9) increased the rate of drug release due 
to Tween 80’s action as a surfactant, which enhanced drug 
solubility in the release medium in addition to lowering the 
PS that itself led to an increase in the surface area of the 
particles.
Differential scanning calorimetry
Figure 7 shows differential scanning calorimetry (DSC) 
thermograms for MZA, the physical mixture composed of 
Compritol, CSA, MZA, and stearylamine, unloaded NLMs, 
and MZA-loaded NLM formula NLM-9. Formula NLM-9 
was chosen for DSC study as it showed high EE% and very 
small PS. MZA showed a sharp, narrow peak at 205.67°C 
with enthalpy of 13.18 J/g representing its melting point and 
confirming its crystalline nature. While the physical mixture 
showed a sharp narrow peak at 48.94°C with enthalpy of 
500 nm
TEM Mag = 60000x 500 nm
TEM Mag = 60000x
500 nm
TEM Mag = 60000x
AB
C
Figure 5 Electron micrographs of MZA-loaded NLMs. (A) NLM-5, (B) NLM-6, (C) NLM-9.
Abbreviations: MZA, methazolamide; NLMs, nanostructured lipid matrices; TEM, transmission electron microscope.
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Figure 7 DSC thermograms for (A) pure MZA, (B) physical mixture, (C) unloaded NLM-9, and (D) MZA-loaded formula NLM-9.
Note: The arrow indicates the MZA peak at 201.10°C in the physical mixture.
Abbreviations: DSC, differential scanning calorimetry; MZA, methazolamide; NLM, nanostructured lipid matrix.
14.46 J/g, this is the average of melting points of Compritol 
and CSA, indicating that both Compritol and CSA are found 
in a crystalline state. It also showed another very small peak 
at 201.10°C (shown by the arrow in Figure 7) with enthalpy 
of 0.09 J/g representing the MZA peak. The small magnitude 
of this peak may be due to the small amount of MZA found 
in the physical mixture. Both unloaded and loaded NLM-9 
formulae gave rise to a broad very small peak at 51.2°C with 
enthalpy of 3.36 J/g and 52.95°C  with  enthalpy 
3.10 J/g, respectively. The broadening of the peak accom-
panied with a decrease in the enthalpy and height of the 
melting peak indicates a decrease in the crystallinity of the 
lipids, which shows that incorporating lipids in NLMs led to 
major defects in the crystal lattice of the lipids, giving rise 
to more space to successfully entrap the drug. The onset of 
the peak of MZA-loaded NLM formula NLM-9 was at 
47.67°C, which confirms the solid nature of lipids when 
exposed to body temperature (as this is above 40°C, 
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Figure 8 X-ray diffraction patterns for (A) MZA, (B) MZA-loaded NLM-9, (C) Compritol, and (D) CSA.
Abbreviations: CSA, cetostearyl alcohol; MZA, methazolamide.
so   avoiding the presence of the nanoemulsion in which the 
advantages of NLMs will be lost). The disappearance of the 
MZA melting peak in the DSC thermogram of NLM-9 indi-
cates that the drug is not in a crystalline state (ie, is 
  amorphous) or molecularly dispersed in the lipid matrix. 
Similar results have been observed by many authors.35,37–39
X-ray diffraction
X-ray diffraction was carried out to evaluate the crystallinity 
of MZA-loaded NLM formula NLM-9 and compare it to that 
of pure MZA, Compritol, and CSA (see Figure 8). The MZA 
X-ray diffractogram shows several sharp, narrow peaks 
between 10° and 40° (2θ) with maximum peak intensity at 
2θ = 13.87° (d = 6.37 Å), indicating its crystalline nature. 
The X-ray diffractogram of CSA showed four major sharp 
peaks with a maximum peak at 2θ = 21.29° (d = 4.16 Å), 
while Compritol showed only two sharp peaks with the 
maximum at 2θ = 21.18° (d = 4.189 Å). In the case of formula 
NLM-9 there was only one major peak at 2θ = 21.15° 
(d = 4.19 Å), which probably represented an overlapped peak 
of both CSA and Compritol. Also, it is clear that the peaks 
of MZA disappeared from the diffraction pattern of NLM-9, 
indicating its amorphous state and confirming the results of 
DSC analysis. It is known that the intensity of peaks is related 
to the crystallinity of the sample, with a higher peak intensity 
indicating that the material is more crystalline. Given that 
the peak intensity of NLM-9 showed a sharp decrease when 
compared to that of Compritol or CSA, this indicates a 
marked decrease in the crystallinity of NLMs and confirms 
previous results from the DSC analysis.
Effect of aging
To assess the effect of aging on the prepared NLMs, mean 
PS was measured following one month of refrigeration; the 
results of this are presented in Figure 9. Student’s t-test 
analysis demonstrated that formulae NLM-1 and NLM-3 
containing 0.5 wt% Tween 80 and formulae NLM-4 and 
NLM-5 containing 1 wt% Tween 80 showed significant 
change in mean PS (P , 0.01). However, all formulae were 
stable at 2 wt% Tween 80, with no significant change in 
mean PS. This indicates that a higher concentration of Tween 
80 leads to very high stability. As a general conclusion, NLMs 
showed very good stability after 1 month, with the mean PS 
of all formulae remaining below 500 nm (including those 
that showed a significant increase in PS). This may be attrib-
uted to the high positive charge induced by the presence of 
stearylamine, which would be expected to cause repulsion 
between particles, so avoiding their aggregation and coales-
cence, in addition to the stabilizing effect of Tween 80.
In vivo study on MZA-loaded NLMs
MZA-loaded NLM formulae NLM-6 and NLM-9 were 
selected for the in vivo studies as they showed higher EE% 
and prolonged drug release patterns. Figure 10 shows the 
reduction in the IOP of selected NLM formulations compared 
to that of MZA solution. It can been seen that the MZA solu-
tion caused the greatest reduction in the IOP effect after 
3 hours, when a value of −4.85 mmHg was recorded, and the 
reduction lasted for a total of 5 hours. On the other hand, the 
IOP-lowering effect of MZA-loaded NLMs reached its peak 
after 3 hours, when values of −6.4 (NLM-6) and −8.3 mmHg 
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Figure 10 reduction in IOP after administration of topical MZA-loaded NLM-6 and NLM-9 compared to MZA solution.
Abbreviations: IOP, intraocular pressure; MZA, methazolamide; NLM, nanostructured lipid matrix.
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Figure 9 Change in mean PS of MZA-loaded NLMs after refrigeration for 1 month at 4°C.
Abbreviations: MZA, methazolamide; NLM, nanostructured lipid matrix.
(NLM-9) were recorded;   reductions lasted for 10 hours and 
about 12 hours, respectively, as shown in Table 5. Entrapping 
MZA in NLMs significantly enhanced its IOP-lowering 
activity and increased its duration of action compared to the 
MZA solution (P , 0.05). It is likely that the increase in 
IOP-lowering activity is due to improved ocular penetration 
of MZA entrapped in NLMs. This may be attributed to their 
lipophilic nature facilitating the penetration of the highly 
hydrophobic epidermis of the cornea.6 Furthermore, the 
increased duration of action might be due to adherence of 
NLMs to ocular membranes, preventing tear wash out owing 
to their small size, cationic charge, and particulate nature.7
The area under the curve (AUC) was calculated as shown 
in Table 5. It can be seen that formula NLM-9 provided the 
highest pharmacological response, followed by formula 
NLM-6; both were significantly (P , 0.05) higher than MZA 
solution. The higher AUC for formula NLM-9 (nearly double 
that of formula NLM-6) may be due to the higher concentra-
tion of Tween 80 (2 wt%), as Tween 80 is a polyoxyethylated 
nonionic surfactant that acts as a penetration enhancer, 
removing the mucus layer and breaking junctional 
complexes,19 so improving MZA ocular permeability. 
In addition, Tween 80 is a P-glycoprotein efflux pump 
inhibitor;40 P-glycoprotein efflux pump is present in the 
cornea,41 so Tween 80’s reduction of the efflux of MZA will 
increase its duration of action.
Gross examination of the rabbit eyes during this study 
did not uncover any signs of abnormal lacrimation or 
increased blinking upon instillation of the prepared NLM 
formulations.
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Conclusion
Cationic MZA-loaded NLMs were successfully prepared 
using heterolipids, and were characterized by mean PS below 
500 nm for all formulations using Tween 80 as an emulsifier. 
The NLMs remained stable for at least 1 month when stored 
at 4°C. Increasing CSA concentration was accompanied by 
an increase in MZA EE%, which reached its highest 
value at 4 wt%. In contrast, various levels of Tween 80 did 
not affect EE%, but PS did drop as Tween 80 concentration 
increased. In vitro release studies showed that both the 
CSA:Compritol ratio and Tween 80 concentration affected 
the release rate of MZA from NLMs. Release could be sus-
tained for about 8 hours. NLMs provided higher EE% and 
slower MZA release rate compared to SLNs, indicating that 
they were superior drug carriers. DSC studies confirmed the 
solid nature of NLMs at room temperature. X-ray diffraction 
pattern analysis showed a marked decrease in NLM 
  crystallinity. In vivo results showed that NLMs were suc-
cessful in ocular delivery of MZA, with no visual irritation 
and a marked decrease in IOP providing a higher pharma-
cological response and more sustained effect than MZA 
solution. This suggests that NLMs are suitable as a topical 
ocular delivery carrier for MZA in treatment of glaucoma.
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